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Abstract Apoptosis was induced in tbymocytes using diverse 
stimuli in order to identify events within a common apoptotic 
pathway. Benzyloxycarbonyl-valinyl-alaninyl-asparty fluoro- 
methyl ketone (Z-VAD.FMK), an interleukin-l/?-converting en- 
zyme (ICE)-like protease inhibitor, inhibited apoptosis assessed 
by flow cytometry, proteolysis of poly (ADP)-ribose polymerase 
(PARP), an early biochemical marker of apoptosis, and cleavage 
of DNA to both large kilobase pair fragments (30-50 and 200- 
300 kbp) and to nucleosomal fragments. Z-VAD.FMK also 
blocked all the classical ultrastructural features of apoptosis in- 
cluding chromatin condensation to one pole of the nucleus, nucle- 
alar disintegration and cytoplasmic vacuolation. These results 
suggest the involvement of an ICE-like protease as a common 
mediator of apoptosis in thymocytes. 
I;ey words: Poly (ADP)-ribose polymerase; Z-VAD.FMK; 
‘l’hymocyte; Apoptosis; ICE inhibitor 
1. Introduction 
There is a growing realisation that apoptosis acts as a coun- 
rebalance to cell proliferation and is of vital importance for 
I ormal development and tissue homeostasis [I]. Apoptosis is 
L common response in many different cell types elicited by 
I iverse stimuli including chemicals, radiation and viruses [l-3]. 
“0 explain this, a model of apoptosis has been proposed in 
> which disparate stimuli activate private signalling pathways, 
1 which converge on a single pathway characterised by a series 
j If common morphological and biochemical changes [4]. Apop- 
osis has been divided into distinct stages using both genetic and 
ijiochemical criteria. Different genes are associated with the 
j decision to die, the execution of a common death programme 
nd the subsequent engulfment and degradation of the dying 
ells [5]. A series of common biochemical and morphological 
hanges is associated with apoptosis [1,4,6] and these are well 
haracterised in thymocytes [7,8]. Briefly, the cell shrinks and 
he chromatin condenses with an attendant cleavage of DNA 
1,7]. Initially DNA is cleaved to 200-300 and 30-50 kilo- 
jasepair size fragments, which are then further degraded to 
jroduce oligonucleosomes and the typical DNA ladder pattern 
9-121. The cytoplasmic changes of apoptosis are characterised 
)y dilatation of the endoplasmic reticulum [l]. 
Protein degradation has also been implicated in apoptosis in 
10th invertebrate and mammalian experimental systems. In the 
nematode, Caenorhahditis elegans, the gene ted-3 is essential for 
cpoptosis and encodes a protein similar to the mammalian 
jrotease, interleukin- I/&converting enzyme (ICE) [ 131. Further 
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work has identified a family of ted-3 related mammalian genes 
whose overexpression results in apoptosis [ 13-201 and one, 
i&l,, is expressed in thymocytes [17]. Thymocyte apoptosis is 
accompanied by calcium-dependent proteolysis and a role for 
calpain, a calcium-dependent neutral protease, has been sug- 
gested [21]. Protease inhibitors can prevent internucleosomal 
DNA cleavage in thymocytes [22], apoptosis in HL-60 cells 
[22.23] and T-cell receptor mediated cell death [24]. In addition 
introduction of exogenous proteases (trypsin, chymotrypsin 
and proteinase K) into cells induces chromatin condensation 
and DNA fragmentation characteristic of apoptosis [25]. We 
have recently shown in thymocytes that TLCK prevents apop- 
tosis induced by diverse stimuli and acts at an early stage of the 
apoptotic process, prior to the formation of large kilobase pair 
fragments of DNA, suggesting that a TLCK-sensitive trypsin- 
like protease is required early in the apoptotic process [26]. 
Specific proteins, including histones. lamins, topoisomerases 1 
and II, poly (ADP ribose)-polymerase (PARP) and Ul small 
nuclear ribonucleoprotein, are degraded during apoptosis 
[ l&19,23,27,28]. Proteolysis of PARP has been proposed as an 
early marker of apoptosis [27,29]. Subsequent work has shown 
that cleavage of PARP is similar in nuclei undergoing chroma- 
tin condensation typical of apoptosis and in cells undergoing 
apoptosis [29]. Thus there is strong evidence that PARP is at 
least one of the cellular targets for an ICE-like protease (prICE) 
and its breakdown may be required for the chromatin conden- 
sation of apoptosis [18,29]. 
To ensure the events studied lie on a common pathway and 
are not specific to a particular agent, we have used several 
different apoptotic stimuli with diverse modes of action and 
assessed the effects of ICE-like protease inhibitors on apopto- 
sis. The stimuli included dexamethasone, a glucocorticoid [7], 
etoposide. a DNA topoisomerase II inhibitor [9] and thapsi- 
gargin, an inhibitor of endoplasmic reticular Ca*‘-ATPase [30]. 
We have also used several criteria to assess apoptosis in order 
to ascertain at what stage(s) the various inhibitors are blocking 
the apoptotic process. Benzyloxycarbonyl-valinyl-alaninyl-as- 
party1 fluoromethyl ketone (Z-VAD.FMK) possesses an aspar- 
tic acid residue in the Pl position and therefore inhibits ICE- 
like proteases [3 1,321. We now demonstrate that in thymocytes 
Z-VAD.FMK inhibits the induction of apoptosis by diverse 
stimuli supporting the involvement of an ICE-like protease as 
a common mediator of thymocyte apoptosis. 
2. Materials and methods 
2.1. Preparution and incubation of thvmocyte suspensions 
Suspensions of thymocytes from immature male F344 rats (45 
weeks old, 65-85 g) were prepared as described previously [33]. Thy- 
mocytes (2 x 10’ cells.ml-‘) were incubated in RPM1 1640 medium 
supplemented with 10% foetal bovine serum in a humidified incubator 
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at 37°C under 5% CO, and 95% air. To induce apoptosis, thymocytes 
were incubated for up to 4 h with either dexamethasone (0.1 PM), 
etoposide (IOpM) or thapsigargin (50 nM). Thymocytes were preincu- 
bated with either Z-VAD.FMK or TLCK for 1 h prior to exposure to 
apoptotic stimuli. 
2.2. Apoptosis assessed byjowa cytometry 
Cells (1 x 106) were stained with Hoechst 33342 and propidium iodide 
[34] and analysis carried out using a Be&on Dickinson Vantage flow 
cytometer with Lysis II software (Becton Dickinson). Viable apoptotic 
thymocytes were separated from normal cells based upon both smaller 
size and higher blue fluorescence with Hoechst 33342 [34]. The in- 
creased Hoechst staining reflects a change in membrane permeability 
and is quantified by flow cytometry [35]. Protease inhibitors were used 
at nontoxic concentrations as assessed by exclusion of propidium io- 
dide. 
2.3. Field inversion and conventional gel electrophoresis 
Agarose plugs (100 ~1) containing 1 x lo6 cells were prepared and 
then subjected to FIGE as previously described [lo]. Whole cells 
(2 x 106) were loaded per lane and conventional electrophoresis carried 
out to detect DNA laddering [36]. 
2.4. Detection of PARP proteolysis 
Cells (5 x 106) were prepared for SDS-PAGE as previously described 
with some modifications [37]. Briefly, 5 x IO6 cells were lysed in sample 
buffer (62.5 mM Tris, 4 M urea, 1 mM EDTA, 1 mM phenylmethane- 
sulfonylfluoride, 2% SDS, 5% B-mercaptoethanol and 0.005% bromo- 
phenol blue pH 6.8), sonicated and boiled for 3 min. Proteins were 
resolved on a 7% SDS-polyacrylamide gel, transferred onto nitrocellu- 
lose and Western blotting carried out using rabbit antiserum (318) to 
PARP (diluted 1 : 8000 in Tris buffered saline 0.1% Tween 20, pH 7.4). 
The antibody to PARP was a gift from Dr. G. Poirier Quebec, Canada. 
Detection was achieved by using a secondary antibody (goat anti-rabbit 
IgGs) conjugated to horseradish peroxidase (diluted 1: 2000 in Tris 
buffered saline, 0.1% Tween 20, pH 7.4) and an ECL detection kit 
(Amersham Life Science, UK). 
2.5. Electron microscopy 
Cells (2 x 106) were fixed and prepared as previously described [38] 
and examined in a Zeiss 902A electron microscope. 
2.6. Materials 
All media and serum were from Gibco (Paisely UK). Pronase and 
TLCK were from Boehringer Mannheim UK (Lewes, UK). Z- 
VAD.FMK was from Enzyme Systems Inc (Dublin, CA, USA). N- 
Acetyl tyrosinyl-valinyl-alaninyl-aspartyl chloromethyl ketone was 
from Bachem (Bubendorf, Switzerland). YVAD.CHO and ben- 
zyloxycarbonyl-valinyl-alaninyl-6-ethylaspartyl- (2,6-dichlorobenzoyl- 
oxy) methyl ketone were provided by Professor L. Rubin (Eisai Labo- 
ratories, London, UK). All other chemicals were from Sigma Chemical 
Company (Poole, UK). 
3. Results 
3.1. Z- VAD. FMK inhibits apoptosis induced by diverse stimuli 
ICE-like proteases play an important role in apoptosis [13- 
20]. Therefore the effects of an ICE-like protease inhibitor, 
Z-VAD.FMK, on thymocyte apoptosis were investigated. Thy- 
mocytes were incubated for 1 h with Z-VAD.FMK (50, 100 or 
200 ,LM) and subsequently incubated for a further 4 h with 
dexamethasone, etoposide or thapsigargin. Apoptosis induced 
by dexamethasone, etoposide and thapsigargin was markedly 
inhibited by Z-VAD.FMK (200 ,LM) (Table 1). In order to 
ascertain at what stage of the apoptotic process Z-VAD.FMK 
was exerting its inhibitory action, DNA fragmentation was 
assessed by both field inversion gel electrophoresis (FIGE) and 
conventional agarose gel electrophoresis. Etoposide, thapsi- 
gargin and dexamethasone induced both the formation of large 
kilobase pair sized fragments, primarily of lo-50 kbp, and also 
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Fig. 1. Z-VAD.FMK prevents DNA fragmentation. Thymocytes were 
incubated for 1 h either alone or with Z-VAD.FMK (50-200 PM). 
Apoptosis was induced by further incubation for 4 h with either eto- 
poside (10 PM) or thapsigargin (50 nM). (a) The formation of large 
kilobase pair sized fragments of DNA was assessed by FIGE. b) Inter- 
nucleosomal cleavage of DNA was detected by conventional agarose 
gel electrophoresis. 
internucleosomal cleavage compared with control cells (Fig. 1 
and data not shown). Z-VAD.FMK caused a concentration 
dependent inhibition of both the formation of large kilobase 
pair sized fragments and DNA laddering (Fig. 1). 
Other inhibitors of ICE-like proteases were examined for 
their ability to prevent apoptosis as assessed by flow cytometry. 
Dexamethasone-induced apoptosis was not inhibited by either 
N-(N-acetyl-tyrosinyl-valinyl-alaninyl)-3-amino~-oxobutanoic 
acid (YVAD.CHO) (100 PM) or benzyloxycarbonyl-valinyl- 
alaninyl-6-ethylaspartyl-(2,6-dichlorobenzoyl-oxy) methyl ke- 
tone (50 ,LLM) (data not shown). At higher concentrations both 
these inhibitors were insoluble in the culture medium. N-Ace- 
tyl-tyrosinyl-valinyl-alaninyl aspartyl chloromethyl ketone (200 
PM) did not inhibit either dexamethasone- or etoposide-in- 
duced apoptosis as assessed by either flow cytometry or con- 
ventional agarose gel electrophoresis (data not shown). 
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Gg. 2. Z-VAD.FMK prevents the morphological changes of apoptosis. Thymocytes were incubated for I h either alone (a, c and e) or with 
Z-VAD.FMK (200 ,uM) (b, d and 1). They were then further incubated for 4 h with dexamethasone (0.1 ,uM) (a and b), etoposide (10 ,uM) (c and 
1) or thapsigargin (50 nM) (e and f). Z-VAD.FMK inhibited the characteristic chromatin condensation of apoptosis induced by dexamethasone, 
:toposide and thapsigargin. Magnification = x 5,600. 
1.2. Morphological changes qf’apoptosis were inhibited by 
Z- VAD. FMK 
Dexamethasone, etoposide and thapsigargin induced classi- 
:a1 ultrastructural features of apoptosis (Fig. 2) including cell 
shrinkage, chromatin condensation to one pole of the nucleus, 
,rucleolar disintegration and cytoplasmic vacuolation. Z- 
VAD.FMK (200 PM). inhibited all these ultrastructural fea- 
lures of apoptosis induced by dexamethasone, etoposide and 
thapsigargin (Fig. 2). The cytoplasm of cells protected with 
Z-VAD.FMK exhibited normal ultrastructure. The nuclei of 
these cells were within the range of morphologies found in 
preparations of untreated thymocytes but the proportion show- 
ing slight condensation of perinuclear heterochromatin was 
increased. In addition to causing ultrastructural changes typical 
of apoptosis, thapsigargin also produced in 5510% of thy- 
mocytes mitochondrial changes, which are not normally associ- 
ated with apoptosis. These mitochondrial changes were not 
inhibited by Z-VAD.FMK (data not shown). Thapsigargin, 
inhibits the microsomal calcium pump resulting in an increase 
in intracellular calcium [30], which may lead to mitochondrial 
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Fig. 3. Z-VAD.FMK and TLCK inhibit PARP proteolysis. Thy- 
mocytes were incubated for 1 h alone, or with either Z-VAD.FMK (200 
PM) or TLCK (50 ,uM). Proteolysis of intact PARP (116 kDa) to an 
85 kDa fragment was induced by further incubation for 4 h with either 
(a) dexamethasone or etoposide (VP16) or (b) thapsigargin. The prote- 
olysis of PARP caused by the apoptotic stimuli was completely or 
partially prevented by Z-VAD.FMK or TLCK, respectively. 
damage by initiating biochemical changes independent of apop- 
tosis. 
3.3. Z- VAD.FMK inhibits PARP proteolysis 
As PARP proteolysis has been reported to be an early bio- 
chemical marker of apoptosis [27,29], we wished to investigate 
whether this was also influenced by Z-VAD.FMK. We have 
previously reported that TLCK (50 PM) prevents apoptosis 
induced by a number of agents [26]. In order to extend these 
observations and compare them with the present studies, thy- 
mocytes were incubated for 1 h in the presence of Z- 
VAD.FMK (200 ,uM) or TLCK (50 PM) and subsequently 
exposed for 4 h to dexamethasone (0.1 PM), etoposide (10 PM) 
or thapsigargin (50 nM). The extent of PARP degradation in 
these cells was then assessed by Western blotting using a poly- 
clonal antibody (318). In control cells and in cells treated with 
Z-VAD.FMK or TLCK alone, the majority of PARP was 
intact (116 kDa) with little or no degradation to an 85 kDa 
product (Fig. 3). Dexamethasone, etoposide and thapsigargin 
caused a decrease in intact PARP accompanied by an increase 
in the 85 kDa product, showing an increased proteolysis 
(Fig. 3). This was more marked with etoposide and thapsigargin 
than with dexamethasone. Z-VAD.FMK (200 PM) almost to- 
tally prevented the proteolysis of PARP induced by dexam- 
ethasone, etoposide and thapsigargin (Fig.3). TLCK was less 
effective at inhibiting the proteolysis of intact PARP (116 
kDa) and the extent of inhibition varied with the nature of 
the apoptotic stimulus (Fig. 3). TLCK was most effective 
at inhibiting dexamethasone-induced proteolysis of PARP 
(Fig. 3). 
H. 0. Fearnhead et al. IFEBS Letters 375 (1995) 283-288 
4. Discussion 
4.1. An ICE-like protease is required at an early stage of 
thymocyte apoptosis 
Dexamethasone, etoposide and thapsigargin induced classi- 
cal ultrastructural features of thymocyte apoptosis involving 
both nuclear and cytoplasmic changes, which were prevented 
by Z-VAD.FMK (Fig. 2). Z-VAD.FMK inhibited dexa- 
methasone-, etoposide- and thapsigargin-induced apoptosis 
(Table 1) and prevented both cleavage of DNA to large kilo- 
basepair size fragments and the formation of DNA ladders 
(Fig. 1). Thus the inhibition of the biochemical changes by 
Z-VAD.FMK correlated closely with the inhibition of morpho- 
logical signs of apoptosis. These data support the involvement 
of an ICE-like protease at an early stage of a common apoptotic 
pathway in thymocytes prior to any detectable biochemical or 
ultrastructural alterations characteristic of apoptosis. 
Recently Z-VAD.FMK has also been shown to inhibit Fas- 
induced apoptosis in Jurkat cells and apoptosis induced by 
diverse stimuli in the human monocytic tumour cell line, THP-1 
[39,40]. The high concentrations of Z-VAD.FMK required for 
inhibition of apoptosis in thymocytes may have been due to 
poor cellular permeability compared to Jurkat or THP-1 cells 
or to nonspecific effects. Fluoromethyl ketones are, however, 
much less reactive than the corresponding chloromethyl 
ketones [41] and so their lack of toxicity at high concentrations 
(Table 1) suggested they were not reacting nonspecifically. Al- 
ternatively high concentrations of Z-VAD.FMK may have 
been required to inhibit a homologue(s) of ICE different from 
those found in Jurkat and THP-1 cells [39,40]. Specific inhib- 
itors of ICE have an aspartate in the P, position together with 
four amino acid residues to the left of the cleavage site [3 11. The 
lack of inhibition of apoptosis by more specific ICE inhibitors, 
such as YVAD.CHO and N-acetyl-tyrosinyl-valinyl-alanyl-as- 
party1 chloromethylketone, suggested that an ICE-like protease 
other than ICE per se may be involved in thymocyte apoptosis. 
This suggestion is in agreement with the recent finding that 
induction of apoptosis in thymocytes and macrophages from 
ICE-deficient mice appeared normal [42] although some differ- 
ences were observed in Fas-induced apoptosis [43]. Inhibition 
of other ICE-like proteases, whilst requiring an aspartate in the 
P, position, will require different residues in the Pz-Pb positions 
[18]. In contrast Z-VAD.FMK, with an aspartate in the P, 
position but no amino acid in the P, position would be expected 
Table 1 
Z-VAD.FMK inhibits apoptosis induced by diverse stimuli 
Treatment Z-VAD.FMK % Apoptotic cells 
Control 9.8 + 1.6 
Control + 8.9 f 3.4 
Dexamethasone 29.9 f 2.6 
Dexamethasone + 10.9 f 3.8 
Etoposide _ 41.5 f 11.6 
Etoposide + 17.1 f 3.8 
Thapsigargin _ 40.0 + 8.6 
Thapsigargin + 18.9 + 2.6 
Thymocytes were incubated for 1 h either alone or with Z-VAD.FMK 
(200pM) and then further incubated for 4 h with either dexamethasone 
(0.1 ,uM), etoposide (10 ,uM) or thapsigargin (50 nM). The percentage 
of apoptotic cells was then assessed by flow cytometry [34]. The data 
represent the mean ( zb S.E.M.) of at least 3 experiments. 
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to have a lower affinity for ICE but should inhibit other ICE- 
like proteases [32]. 
4.3. PARP proteolysis 
Degradation of PARP has been proposed as an early marker 
ol’apoptosis [27]. In thymocytes dexamethasone, and etoposide 
ii duced proteolysis of intact PARP (116 kDa) with the con- 
c bmitant generation of an 85 kDa fragment (Fig. 3), consistent 
b Ith previous reports [23,27,29]. Thapsigargin also induced 
poteolysis of PARP and the appearance of an 85 kDa frag- 
n ent (Fig. 3). Z-VAD.FMK was very effective at inhibiting 
P \RP proteolysis induced by all three stimuli (Fig. 3) further 
sipporting our hypothesis that Z-VAD.FMK was inhibiting 
a ,optosis at an early stage of a common pathway. As one of 
tlie mammalian homologues of ICE, variously known as 
I -ICE, CPP32 or Yama, has been implicated in cleaving PARP 
a rd being important for the initiation of apoptotic cell death 
[ 8,19,29], it was possible that in thymocytes, Z-VAD.FMK 
v as inhibiting this protease either directly or indirectly. 
Our previous studies had implicated both a trypsin-like and 
a chymotrypsin-like serine protease at an early and late stage 
c f thymocyte apoptosis [26]. In the present study, we also impli- 
c ite an ICE-like protease suggesting the involvement of multi- 
1 le proteases in apoptosis in thymocytes in agreement with a 
s milar proposal of multiple proteases being involved in Fas- 
i educed apoptosis in Jurkat cells [39]. TLCK also inhibited 
1 ARP proteolysis induced by all three stimuli (Fig. 3) support- 
i ig our earlier suggestion that TLCK was inhibiting thymocyte 
2 poptosis at an early stage [26]. However in our recent study 
\ ith THP-1 cells, Z-VAD.FMK inhibited apoptosis whereas 
-“LCK potentiated apoptosis by most stimuli [40]. These results 
~dggested that the TLCK target was not part of a common 
t ffector mechanism but that it had an important function either 
1 ositively or negatively regulating apoptosis dependent on the 
cell type. In contrast the ability of Z-VAD.FMK to inhibit 
;‘poptosis induced by diverse stimuli in several different systems 
( 19, 40, 44 and the present study] support the hypothesis that 
; is inhibiting a common mediator of apoptosis. This common 
I mediator of apoptosis in both the nematode and mammals 
,#ppears to be a ted-3/ICE-like cysteine protease [13-201. The 
pecific homologue(s) of ICE involved in the induction of apop- 
Jsis in thymocytes remains to be elucidated. 
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